The differing types of EDS are a result of faults in certain genes that make connective tissue weaker.Novel drug therapies may be developed taking into consideration the opportunity role of a dysfunctional extracellular matrix on discomfort modulation in EDS, as all readily available therapeutic methods exhibit a very low evidence of efficacy from